Navigation Links
Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
Date:6/2/2009

SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that additional results from its North American Phase 3 clinical study of fidaxomicin in patients with Clostridium difficile infection (CDI) were presented today by clinical investigator, Mark A. Miller, M.D., at the Digestive Disease Week 2009 conference in Chicago.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

The additional data presented today for the first time focused on other patient risk factors believed to be predictive of CDI recurrence following treatment. These risk factors include serum albumin levels, white blood cell (WBC) count and temperature, and non-BI (NAP1/027) strains. The data showed that fidaxomicin overall demonstrated a lower recurrence rate compared to oral vancomycin (Vancocin(R)) regardless of albumin levels, WBC count and temperature, as well as for patients with non-BI (NAP1/027) strains. Vancocin is currently the only FDA approved therapy for CDI.

Recurrence Rates by Subgroup (per protocol)

    -------------------------------------------------------------------------
    Risk Factors                         Fidaxomicin     Vancocin(R) capsules
                                         (200mg bid)         (125mg qid)
    -------------------------------------------------------------------------
    White Blood Cell Count /Temp
    -------------------------------------------------------------------------
    WBC < 15,000 uL and Temp
     < 38 degrees C                     10.7% (17/159)      22.4% (35/156)
    WBC 15-25,000 uL or Temp 38
     degrees - 39 degrees C             12.0% (3/25)        20.0% (6/30)
    WBC > 25,000 uL or Temp
   
'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 ­ RedBrick Health ... behavior change technology, today announces that EmblemHealth , ... and wellness company, is now providing the RedBrick Compass ... coaching program, to all of its members. EmblemHealth is ...
(Date:1/15/2014)... NY (PRWEB) January 15, 2014 The Microcompetition ... a major disease. One of these latent viruses is the ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory ... theory, a study found that RA patients have high concentrations ...
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s ... better care of my furry companion." Nowadays there are pet salons, ... cases to take the little canine or feline darlings along wherever ... buy some pricey toys at the pet store. But anyone who ...
Breaking Biology Technology:EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... Clinton will,participate as one of the main speakers at the ... in Sao Paulo, Brazil. The event is organized by the,Brazilian ... gatherings focused on biofuels in the world. , ... a second term,in six decades. After leaving the White House, ...
... - Aegera Therapeutics is pleased to announce the ... for AEG33773, a novel, orally bio-available small molecule ... neuropathy. , The Phase 2a study, entitled A ... and Efficacy of AEG33773 versus Placebo in Patients ...
... announced successful,completion of the single-day oral dosing part ... patients with its new anti-cancer drug AXL1717,an,insulin-like growth ... the closely related insulin receptor. The study is ... The results showed that a single-day,dosing of AXL1717 ...
Cached Biology Technology:President Bill Clinton to Speak at the Ethanol Summit in Brazil 2Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain 2Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB 2
(Date:4/18/2014)... crystallography and nuclear magnetic resonance imaging (NMR) to gain ... such efforts have long been hampered by the fact ... and often in ordered and crystalized form to be ... into the structure of most molecules. , Harvard researchers, ... of the past. , A team of scientists, ...
(Date:4/18/2014)... the past 20 years, researchers have published soil organic ... have suggested that soil organic carbon can be sequestered ... to no-till systems. However, there is a growing body ... and soybean rotations without cover crops, small grains, and ... at the published rates. , "Some studies have shown ...
(Date:4/18/2014)... Durham, NC Seeds that sprout as soon as they,re ... plants need to be more careful. In the wild, a ... rainy day would risk disaster. More than just an insurance ... out that seed dormancy has long-term advantages too: Plants ... give rise to more species, finds in a team of ...
Breaking Biology News(10 mins):MRI, on a molecular scale 2MRI, on a molecular scale 3Researchers question published no-till soil organic carbon sequestration rates 2Researchers question published no-till soil organic carbon sequestration rates 3Researchers question published no-till soil organic carbon sequestration rates 4Plants with dormant seeds give rise to more species 2
... may aid the quest for accurate, low-cost genomic sequencing, according ... by Stuart Lindsay and his collaborators at the Biodesign Institute ... an electron, can cross a barrier, when, according to classical ... Unraveling the DNA sequences of the human genome a ...
... N.J., March 4 BIO-key International, Inc. (OTC Bulletin ... finger-based biometric identification solutions, today announced that on or ... United States District Court for the Southern District of ... two of the Company,s investors, Longview Special Finance, Inc. ...
... Detects Faces in Motion, Matches with Watch-list ... Lithuania, March 9 Neurotechnology, a provider ... the availability of VeriLook Surveillance SDK, a ... using live video streams from high-resolution digital ...
Cached Biology News:Covering the bases: Quantum effect may hold promise for low-cost DNA sequencing, sensor applications 2Covering the bases: Quantum effect may hold promise for low-cost DNA sequencing, sensor applications 3Covering the bases: Quantum effect may hold promise for low-cost DNA sequencing, sensor applications 4BIO-key to Respond in Court to a Lawsuit Filed by Two Investors 2BIO-key to Respond in Court to a Lawsuit Filed by Two Investors 3VeriLook Surveillance SDK Provides Real-Time Face Identification Using Video Surveillance Cameras 2VeriLook Surveillance SDK Provides Real-Time Face Identification Using Video Surveillance Cameras 3
Homo sapiens olfactomedin 1, transcript variant 3...
RABBIT ANTI QUINOLINIC ACID...
Coverslips for Microarrays, 1. *Category: MICROARRAY ACCESSORIES....
Agarase cleaves agarose to neoagaro-oligosaccharides, and is used for,quantitative, gentle recovery of DNA from low melting point agarose....
Biology Products: